How many Aviva shares must I buy to give up work and live off the income?

Aviva shares are on track to pay a 6.7% yield in 2026, generating a highly tempting stream of passive dividend income. But is this actually a good investment?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Man hanging in the balance over a log at seaside in Scotland

Image source: Getty Images

Aviva (LSE:AV.) shares are starting to look highly tempting for many income investors. That’s because if analyst forecasts are correct, the dividend per share could be on track to reach 41.6p by the end of 2026, placing the insurance stock’s forward yield at a tasty-looking 6.73%.

This projected payout is more than double the 3.13% currently being offered by FTSE 100 index funds. And it means anyone who’s trying to replace their salary with passive income will need a much smaller portfolio compared to index investors.

So just how many Aviva shares does someone need to buy to achieve this goal? And is it even a good idea?

Crunching the numbers

The median average salary in the UK is around £32,890 a year. At a 3.13% yield, a passive index fund investor would need to have a massive £1,050,799 portfolio.

But for anyone earning 6.73% from Aviva shares, the required portfolio size drops sharply to £488,707 – less than half. And in terms of the actual number of shares an investor would need to buy, that’s around 79,063.

Obviously, not everyone has the luxury of having almost half a million pounds sitting on the sidelines ready to be invested today. But the good news is, even someone starting from scratch today can eventually build to this chunky six-figure nest egg by consistently investing each month.

So are Aviva shares actually a good long-term investment?

The bull case

Operationally speaking, Aviva’s performance in 2025 was genuinely outstanding. With the business shifting towards a capital-light business model, underlying operating profits jumped 25%, while earnings per share (EPS) charged ahead by 17%.

And with the bottom line expanding by double digits, not only did the company achieve its 2026 targets a year ahead of schedule, but it also marked the fifth consecutive year of strong, profitable business expansion.

What’s more, the business has just outlined new three-year profit targets for 2028 that are even more ambitious, including a target of 20%+ for return on equity, and an 11% average annualised growth rate for EPS.

Not only does this signal strong confidence from management, but double-digit earnings growth also paves the way for even more sustained dividend expansion. In other words, the already impressive dividend yield could get even bigger in the coming years.

What to watch

Even with impressive 2025 results, there’s one major blemish ultimately weighing Aviva shares down – it’s the Solvency II ratio.

As a quick crash course, the Solvency II ratio measures how much capital an insurance firm holds above the regulatory minimum. And in 2025, Aviva’s ratio dropped from 203% to 180%.

Digging a bit deeper, the sudden drop is largely being driven by its Direct Line acquisition, among other factors. So far, integrating Direct Line seems to be going smoothly. And once the firm unlocks all the expected synergies from this deal, the Solvency II ratio should start to recover. But of course, that all boils down to execution risk.

So where does that leave investors today? All things considered, Aviva shares currently present a compelling passive income opportunity, in my opinion. The insurance stock is far from risk-free. But for investors looking for a higher-yielding investment, this business is definitely worth mulling.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »